In a Phase IIa clinical trial, 3TC was found to significantly reduce levels of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid of individuals with early Alzheimer's disease, suggestive of reduced neuroinflammation.104. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.